Evaluation of factors associated with glucocorticoid-induced osteopenia in patients with rheumatic diseases.
Evaluation of factors associated with glucocorticoid-induced osteopenia in patients with rheumatic diseases.
复制标题
风湿病患者糖皮质激素引起的骨质减少相关因素的评估。
作者：
T. R. Dykman;T. R. Dykman;O. Gluck;O. Gluck;W. Murphy;T. Hahn;T. Hahn;B. Hahn;B. Hahn
对161例长期接受强的松治疗的风湿性疾病患者，用单光子骨密度仪测量前臂骨干质量(DM)和干骺端质量(MM)，并复习X线骨片。对治疗和患者特征的多变量分析表明，糖皮质激素引起的骨量减少(定义为DM：MM比率升高)和骨折在不同性别、白人和黑人、各种风湿病患者以及接受不同方案的泼尼松治疗的患者中发生的频率相似。然而，大剂量的泼尼松累积剂量与DM：mm比值升高以及骨折有关，而绝经或年龄大于或等于50岁(男性或女性)与骨折有关。我们的结论是，长期使用不同的强的松治疗方案会导致糖皮质激素引起的骨量减少和骨折。这种影响是累积性的，在所有患者组中都会发生，并在某些组中导致更多的骨折。
In 161 ambulatory rheumatic disease patients receiving long-term prednisone therapy, diaphyseal mass (DM) and metaphyseal mass (MM) of the forearm were measured by single photon absorptiometry, and bone radiographs were reviewed when available. Multivariate analysis of treatment and patient characteristics demonstrated that glucocorticoid-induced osteopenia (defined as an elevated DM:MM ratio) and bone fractures occurred with similar frequency in patients of each sex, in whites and blacks, in patients with various rheumatic diseases, and in patients receiving different regimens of prednisone therapy. However, large cumulative doses of prednisone were associated with elevated DM:MM ratios as well as with bone fractures, and menopause or age greater than or equal to 50 years (males or females) was associated with bone fractures. We conclude that long-term therapy with various prednisone regimens results in glucocorticoid-induced osteopenia and fractures. This affect is cumulative, occurs in all patient groups, and results in more bone fractures in certain groups.
更年期雌激素治疗和髋部骨折。
影响因子：
39.2
作者：
Paganini-Hill,A;Ross,RK;Gerkins,VR;Henderson,BE;Arthur,M;Mack,TM
通讯作者：
Mack,TM
内分泌功能障碍对中轴和附肢骨骼的不同影响。
DOI：
10.1172/jci110570
发表时间：
1982
期刊：
The Journal of clinical investigation
影响因子：
--
作者：
Seeman,E;Wahner,HW;Offord,KP;Kumar,R;Johnson,WJ;Riggs,BL
通讯作者：
Riggs,BL